Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD / Jonathan A. Nowak, MD, PhD - The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to I

Go online to PeerView.com/ZEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies and immunotherapy-based combinations have become key components in the cancer treatment arsenal, and testing for predictive biomarkers to refine patient selection is of increasing importance. Assessment of PD-L1 expression plays an essential role in a number of tumor types, determination of MSI/MMR and TMB status has a place in current practice as well, and many other putative biomarkers are undergoing evaluation. To realize the potential of precision immuno-oncology, pathologists and oncologists must come together and establish effective communication and workflows for immunotherapy biomarker testing and interpretation of results to accurately guide clinical decisions. This PeerView educational activity based on a recent web broadcast highlights important recent advances with immune checkpoint inhibitors and combinations in lung, gastrointestinal, and other cancers, and provides practical guidance for implementing biomarker testing in modern pathology and oncology practice. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established and emerging biomarkers and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.